January 12-15 | San Francisco Marriott Marquis
January 12-16 | Virtual
Evox Therapeutics
At Evox Therapeutics, we focus on tackling genetically defined CNS disorders using exosome-based genome-editing therapeutics. Our lead programs address SCA2/ALS targeting ATXN2 and Huntington’s disease targeting MSH3